IPOs
Filter News
Found 16,632 articles
-
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
5/8/2023
Legend Biotech Corporation today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering.
-
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
5/8/2023
TransMedics Group, Inc. today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes.
-
Savara Announces New Employment Inducement Grant - May 5, 2023
5/5/2023
Savara Inc. today announced the grant of inducement awards to two new employees.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/5/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia’s 2023 Inducement Plan.
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5/5/2023
ORIC Pharmaceuticals, Inc. today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.
-
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5/5/2023
Mereo BioPharma Group plc today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.
-
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Jaguar Health, Inc. today announced that, effective May 2, 2023, the Company granted 100 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2.
-
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/5/2023
NeuroOne Medical Technologies today announced that, effective May 1, 2023, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - May 5, 2023
5/5/2023
Rhythm Pharmaceuticals, Inc. today announced that on May 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 76,440 shares of its common stock to 16 new employees.
-
Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation
5/5/2023
Catalent, Inc. (“Catalent”) (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Apellis Pharmaceuticals, Inc. today announced that the company approved the grant of equity awards to 13 new employees with a grant date of May 1, 2023.
-
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency
5/5/2023
Regulatory News: Aptorum Group Limited today announced that it has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(1)(A).
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Chinook Therapeutics, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023.
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc.
-
Algernon Pharmaceuticals Announces Closing of Rights Offering
5/5/2023
Algernon Pharmaceuticals Inc. announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “ Rights Offering ”).
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Arcutis Biotherapeutics, Inc. today reported the grant of an aggregate of 84,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 15,000 shares of Arcutis’ common stock to nine newly hired employees.
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Fulcrum Therapeutics, Inc. today announced that the Company granted non-statutory stock options to new employees.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Mirati Therapeutics, Inc. today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company.
-
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023
5/5/2023
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 89,559 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.